# FDA Approves Zydus Lifesciences' Generic Ivermectin Oral Formulation Zydus Lifesciences Limited received FDA approval for its generic ivermectin oral formulation, expanding the competitive landscape in the antiparasitic market and potentially increasing pricing pressure on existing branded and generic alternatives. The approval adds another manufacturer to the ivermectin market, which could enhance patient access while continuing to compress margins across the generic segment.